Insulet Corp. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Insulet Corp. has filed its Q1 2024 10-Q report detailing financial performance and operations for the quarter ending March 31, 2024.</b>

AI Summary

INSULET CORP (PODD) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Insulet Corp. filed its 10-Q report for the quarterly period ended March 31, 2024. The filing covers the period from January 1, 2024, to March 31, 2024. The company's principal executive offices are located at 100 Nagog Park, Acton, MA 01720. Insulet Corp. is incorporated in Delaware and operates in the Surgical & Medical Instruments & Apparatus industry. The filing was made on May 10, 2024, with the SEC.

Why It Matters

For investors and stakeholders tracking INSULET CORP, this filing contains several important signals. This 10-Q filing provides investors with the latest financial data and operational updates for Insulet Corp., crucial for assessing the company's current performance and future outlook. Understanding the details within this report allows stakeholders to evaluate Insulet's financial health, revenue streams, and any potential risks or opportunities presented during the first quarter of 2024.

Risk Assessment

Risk Level: — INSULET CORP shows moderate risk based on this filing. The company operates in the medical device industry, which is subject to significant regulatory oversight and rapid technological advancements, posing inherent risks to sustained growth and profitability.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-Q to understand Insulet's performance and strategic positioning in the competitive diabetes management market.

Key Numbers

• 2024-03-31 — Conformed Period of Report (Quarterly period ended)
• 2024-05-10 — Filing Date (Date the report was filed)
• 001-33462 — SEC File Number (Associated SEC file number)
• 978-600-7000 — Business Phone (Company contact phone number)

Key Players & Entities

• INSULET CORP (company) — FILER
• 100 NAGOG PARK (location) — BUSINESS ADDRESS
• ACTON (location) — BUSINESS ADDRESS CITY
• MA (location) — BUSINESS ADDRESS STATE
• 01720 (location) — BUSINESS ADDRESS ZIP
• DE (location) — STATE OF INCORPORATION
• 3841 (industry) — STANDARD INDUSTRIAL CLASSIFICATION
• 2024-03-31 (date) — CONFORMED PERIOD OF REPORT

FAQ

Industry Context

Insulet Corp. operates in the medical device sector, specifically focusing on diabetes management technology. This industry is characterized by innovation, regulatory scrutiny, and a growing patient population requiring advanced treatment solutions.

Regulatory Implications

As a medical device company, Insulet Corp. is subject to regulations from bodies like the FDA in the United States and similar international health authorities, governing product development, manufacturing, and marketing.

What Investors Should Do

1. Analyze the revenue breakdown by segment (e.g., U.S. Omnipod, International Omnipod) to understand growth drivers.
2. Examine the balance sheet for changes in assets, liabilities, and equity compared to the previous period.
3. Review any disclosed risk factors or management discussion and analysis for insights into operational challenges or strategic initiatives.

Key Dates

• 2024-03-31: Quarter End — End of the reporting period for the 10-Q filing.
• 2024-05-10: Filing Date — Date the 10-Q report was officially submitted to the SEC.

Year-Over-Year Comparison

This filing represents the first quarterly report for Insulet Corp. in fiscal year 2024, providing an update on its financial and operational performance following the close of the first quarter.

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 Par Value Per Share PODD The NASDAQ Sto
• $1,000 — te of 4.4105 shares of common stock per $1,000 principal amount of the notes, which is

Filing Documents

• podd-20240331.htm (10-Q) — 890KB
• podd-exx101x2024x03x31_10q.htm (EX-10.1) — 18KB
• podd-exx311x2024x03x31_10q.htm (EX-31.1) — 10KB
• podd-exx312x2024x03x31_10q.htm (EX-31.2) — 10KB
• podd-exx321x2024x03x31_10q.htm (EX-32.1) — 7KB
• 0001145197-24-000022.txt (&nbsp;) — 6095KB
• podd-20240331.xsd (EX-101.SCH) — 41KB
• podd-20240331_cal.xml (EX-101.CAL) — 70KB
• podd-20240331_def.xml (EX-101.DEF) — 279KB
• podd-20240331_lab.xml (EX-101.LAB) — 546KB
• podd-20240331_pre.xml (EX-101.PRE) — 423KB
• podd-20240331_htm.xml (XML) — 861KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements (Unaudited)

Item 1. Condensed Consolidated Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets (Unaudited) as of March 31, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Income (Unaudited) for the three months ended March 31, 2024 and 2023 4 Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the three months ended March 31, 2024 and 2023 5 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) for the three months ended March 31, 2024 and 2023 6 Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended March 31, 2024 and 2023 7 Notes to Condensed Consolidated Financial Statements (Unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 17

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 24

Controls and Procedures

Item 4. Controls and Procedures 24

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 26

Risk Factors

Item 1A. Risk Factors 26

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 26

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 26

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 26

Other Information

Item 5. Other Information 26

Exhibits

Item 6. Exhibits 26

Signatures

Signatures 27 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (Unaudited) INSULET CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in millions, except share and per share data) March 31, 2024 December 31, 2023 ASSETS Current Assets Cash and cash equivalents $ 751.2 $ 704.2 Accounts receivable trade, less allowance for credit losses of $ 3.5 and $ 2.5 234.1 240.2 Accounts receivable trade, net — related party 86.4 119.5 Inventories 430.6 402.6 Prepaid expenses and other current assets 116.1 116.4 Total current assets 1,618.4 1,582.9 Property, plant and equipment, net 667.7 664.9 Other intangible assets, net 98.5 98.7 Goodwill 51.7 51.7 Other assets (includes $ 29.4 and $ 31.3 at fair value) 187.7 190.0 Total assets $ 2,624.0 $ 2,588.2 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable $ 75.9 $ 19.2 Accrued expenses and other current liabilities 308.6 373.7 Accrued expenses and other current liabilities — related party 9.0 8.9 Current portion of long-term debt 38.9 49.4 Total current liabilities 432.4 451.2 Long-term debt, net 1,362.6 1,366.4 Other liabilities 38.3 37.9 Total liabilities 1,833.3 1,855.5 Commitments and contingencies (Note 12) Stockholders' Equity Preferred stock, $ .001 par value, 5,000,000 authorized; none issued and outstanding — — Common stock, $ .001 par value, 100,000,000 authorized; 70,020,202 and 69,907,289 issued and outstanding 0.1 0.1 Additional paid-in capital 1,117.6 1,102.6 Accumulated deficit ( 326.5 ) ( 378.0 ) Accumulated other comprehensive (loss) income ( 0.5 ) 8.0 Total stockholders' equity 790.7 732.7 Total liabilities and stockholders' equity $ 2,624.0 $ 2,588.2 The accompanying notes are an integral part of these condensed consolidated finan ci al statements. 3 Table of Contents INSULET CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Three Months Ended March 31, (in millions, except share and pe

View Full Filing

View this 10-Q filing on SEC EDGAR